Hepatitis C virus (HCV) causes chronic hepatitis, which can progress to cirrhosis and hepatocellular carcinoma. The World Health Organization estimates that approximately 2.35% of the world population (∼160 million individuals) is infected with HCV. Another widespread disorder, metabolic syndrome, comprises a group of correlated clinical features that have insulin resistance as a common pathogenic determinant; it can lead to type 2 diabetes mellitus, nonalcoholic fatty liver disease, cardiovascular disorders, and many types of cancer, including hepatocellular carcinoma. Metabolic syndrome is pandemic; its estimated prevalence in the United States is ∼25%. It is important to determine the relationship between HCV infection and metabolic syndrome.
Rid your body of weight and toxins. Not all colon cleansers are safe and effective.
Read our recommendations BEFORE you buy!
The prognosis and management of patients with chronic viral hepatitis B and C depend on the amount and progression of liver fibrosis and the risk for cirrhosis. Liver biopsy, traditionally considered to be the reference standard for staging of fibrosis, has been challenged over the past decade by the development of noninvasive methodologies. These methods rely on distinct but complementary approaches: a biologic approach, which quantifies serum levels of biomarkers of fibrosis, and a physical approach, which measures liver stiffness by ultrasound or magnetic resonance elastography. Noninvasive methods were initially studied and validated in patients with chronic hepatitis C but are now used increasingly for patients with hepatitis B, reducing the need for liver biopsy analysis. We review the advantages and limitations of the noninvasive methods used to manage patients with chronic viral hepatitis B or C infection.
Rid your body of weight and toxins. Not all colon cleansers are safe and effective.
Read our recommendations BEFORE you buy!
However, breast cancer survival rates were best among 13 industrialized nations
Rid your body of weight and toxins. Not all colon cleansers are safe and effective.
Read our recommendations BEFORE you buy!
Title: Fish Oil Doesn’t Cut Failure Rate of Hemodialysis Grafts
Category: Health News
Created: 5/1/2012 6:05:00 PM
Last Editorial Review: 5/2/2012 12:00:00 AM
Rid your body of weight and toxins. Not all colon cleansers are safe and effective.
Read our recommendations BEFORE you buy!
Title: Fish Oil Doesn’t Cut Failure Rate of Hemodialysis Grafts
Category: Health News
Created: 5/1/2012 6:05:00 PM
Last Editorial Review: 5/2/2012 12:00:00 AM
Rid your body of weight and toxins. Not all colon cleansers are safe and effective.
Read our recommendations BEFORE you buy!
The prognosis and management of patients with chronic viral hepatitis B and C depend on the amount and progression of liver fibrosis and the risk for cirrhosis. Liver biopsy, traditionally considered to be the reference standard for staging of fibrosis, has been challenged over the past decade by the development of noninvasive methodologies. These methods rely on distinct but complementary approaches: a biologic approach, which quantifies serum levels of biomarkers of fibrosis, and a physical approach, which measures liver stiffness by ultrasound or magnetic resonance elastography. Noninvasive methods were initially studied and validated in patients with chronic hepatitis C but are now used increasingly for patients with hepatitis B, reducing the need for liver biopsy analysis. We review the advantages and limitations of the noninvasive methods used to manage patients with chronic viral hepatitis B or C infection.
Rid your body of weight and toxins. Not all colon cleansers are safe and effective.
Read our recommendations BEFORE you buy!
Molecular biology techniques are routinely used to diagnose and monitor treatment of patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These tools can detect and quantify viral genomes and analyze their sequence to determine their genotype or subtype and to identify nucleotide or amino acid substitutions associated with resistance to antiviral drugs. They include real-time target amplification methods, which have been standardized and are widely used in clinical practice to diagnose and monitor HBV and HCV infections, and next-generation sequencing techniques, which are still restricted to research laboratories. In addition, new enzyme immunoassays can quantify hepatitis B surface and hepatitis C core antigens, and point-of-care tests and alternatives to biologic tests that require whole-blood samples obtained by venipuncture have been developed. We review these new virologic methods and their clinical and research applications to HBV and HCV infections.
Rid your body of weight and toxins. Not all colon cleansers are safe and effective.
Read our recommendations BEFORE you buy!
Recently developed drugs and innovative strategies for the treatment of chronic infection with genotype 1 hepatitis C virus (HCV) have become the standard of care. The protease inhibitors telaprevir (Incivek) and boceprevir (Victrelis) are the first direct-acting antiviral (DAA) agents approved, and many more are being developed. These drugs substantially increased rates of sustained virologic response in treatment-naïve and -experienced patients, in conjunction with peginterferon and ribavirin (triple therapy), in phase 3 trials. The efficacy of triple therapy depends on appropriate selection of patients, although the population of patients that receive triple therapy could be expanded as the risk/benefit ratio improves. Attention to details that reflect the standard of care, such as appropriate dosing, anticipation of adverse effects, and strict adherence to stopping rules, will insure the success of these drugs and lead the way for new combination therapies.
Rid your body of weight and toxins. Not all colon cleansers are safe and effective.
Read our recommendations BEFORE you buy!
With the development of effective therapies against human immunodeficiency virus (HIV), hepatitis C virus (HCV) infection has become a major cause of morbidity and mortality among patients with both infections (coinfection). In addition to the high prevalence of chronic HCV, particularly among HIV-infected injection drug users, the rate of incident HIV infections is increasing among HIV-infected men who have sex with men, leading to recommendations for education and screening for HCV in this population. Liver disease is the second leading and, in some cases, a preventable cause of death among coinfected patients. Those at risk for liver disease progression are usually treated with a combination of interferon (IFN) and ribavirin (RBV), which is not highly effective; it has low rates of sustained virologic response (SVR), especially for coinfected patients with HCV genotype 1 and those of African descent. Direct-acting antivirals might overcome factors such as immunodeficiency that can reduce the efficacy of IFN. However, for now it remains challenging to treat coinfected patients due to interactions among drugs, additive drug toxicities, and the continued need for combination therapies that include pegylated IFN. Recently developed HCV protease inhibitors such as telaprevir and boceprevir, given in combination with pegylated IFN and RBV, could increase the rate of SVR with manageable toxicity and drug interactions. We review the latest developments and obstacles to treating coinfected patients.
Rid your body of weight and toxins. Not all colon cleansers are safe and effective.
Read our recommendations BEFORE you buy!
New study found decrease in inflammation warning signals
Rid your body of weight and toxins. Not all colon cleansers are safe and effective.
Read our recommendations BEFORE you buy!
0
Back to top